Hells | helicase, lymphoid specific
Physiological systems
22 / 24 physiological systems tested
6 Significantly impacted by the knock-out
Homeostasis/metabolism Immune system Hematopoietic system Behavior/neurological Cardiovascular system Mortality/aging
16 No significant impact
2 Not tested
Data collections
Gene metrics:10Significant phenotypes
2Associated diseases
Expression examined in:70Adult tissues
0Embryo tissues
| increased cardiac stroke volume | 1 supporting dataset | Hellstm1b(EUCOMM)Wtsi | heterozygote | Early adult | 3.63x10-11 | ||
| abnormal gait | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 5.85x10-7 | ||
| increased CD8-positive, alpha-beta T cell number | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 2.29x10-5 | ||
| dilated heart left ventricle | 2 supporting datasets | Hellstm1b(EUCOMM)Wtsi | heterozygote | Early adult | 8.36x10-7 | ||
| preweaning lethality, complete penetrance | 1 supporting dataset | Hellstm1b(EUCOMM)Wtsi | homozygote | Early adult | N/A * | ||
| decreased heart rate | 1 supporting dataset | Hellstm1b(EUCOMM)Wtsi | heterozygote | Early adult | 6.19x10-7 | ||
| decreased monocyte cell number | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 2.74x10-6 | ||
| decreased circulating cholesterol level | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 1.59x10-5 | ||
| decreased circulating triglyceride level | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 6.13x10-9 | ||
| decreased circulating LDL cholesterol level | 1 supporting dataset | Hellstm1a(EUCOMM)Wtsi | homozygote | Early adult | 7.52x10-5 |
| | | | | | | | | | |
| adrenal gland | heterozygote | n/a | 0% (0/2) | 0.7% (4/570) |
| aorta | heterozygote | n/a | 0% (0/2) | 0.19% (1/533) |
| blood | heterozygote | n/a | 0% (0/2) | 0% (0/17) |
| bone | heterozygote | n/a | 0% (0/2) | 0% (0/394) |
| bone marrow | heterozygote | n/a | 0% (0/2) | 0% (0/22) |
| brain | heterozygote | n/a | 0% (0/2) | 0.86% (5/579) |
| brainstem | heterozygote | n/a | 0% (0/2) | 0.41% (2/490) |
| brown adipose tissue | heterozygote | n/a | 0% (0/2) | 0% (0/588) |
| cartilage tissue | heterozygote | n/a | 0% (0/2) | 0.22% (1/454) |
| cecum | heterozygote | Wholemount images | 100% (2/2) | 7.75% (22/284) |
Human diseases caused by Hells mutations
The analysis uses data from IMPC, along with published data on other mouse mutants, in comparison to human disease reports in OMIM, Orphanet, and DECIPHER.
Phenotype comparisons summarize the similarity of mouse phenotypes with human disease phenotypes.
External links
No external links available for Hells.
All available products are supplied via our member's centres or partnerships. When ordering a product from the IMPC you will be redirected to one of their websites or prompted to start an email.
| Hellstm1a(EUCOMM)Wtsi | KO first allele (reporter-tagged insertion with conditional potential) | | targeting vector ES Cell mouse |
| Hellstm1b(EUCOMM)Wtsi | Reporter-tagged deletion allele (with selection cassette) | | mouse |
| Hellstm1e(EUCOMM)Wtsi | Targeted, non-conditional allele | | ES Cell |
| Hellstm2e(EUCOMM)Wtsi | Targeted, non-conditional allele | | ES Cell |
| Hellstm44592(L1L2_gt0) | KO first allele (reporter-tagged insertion with conditional potential) | | targeting vector |